Ixmyelocel-T: Patient-specific Multicellular Therapy
Ixmyelocel-T is an investigational, patient-specific cell therapy in development at Aastrom for the treatment of severe, chronic cardiovascular diseases. It is derived from a patient's own bone marrow, which is collected by a physician and then processed at Aastrom. This short video explains this process and summarizes the latest clinical study of ixmyelocel-T in patients with critical limb ischemia.
For more information, visit aastrom.com/cell-therapy/product-overview/
Living with Critical Limb Ischemia
In this video, Rosemary and Dick Hough talk about the detrimental effects of critical limb ischemia. To learn more about CLI, visit aastrom.com/patients/about-critical-limb-ischemia/
BioMedReports Interviews Tim Mayleben, President & CEO, Aastrom Biosciences
In this interview, Tim Mayleben offers his prospective on the potential market for ixmyelocel-T, the company's lead product candidate for critical limb ischemia and dilated cardiomyopathy.